Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : APPI - Advanced Plant Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (1253)	5/21/2003 3:49:04 PM
From: SCOOBEY-DO	Read Replies (1) \| Respond to of 1263

Advanced Plant Pharmaceuticals, Inc. and Union Bless, Ltd. HongKong to Conduct Research for SARS; Provisional Patent Application Filed for SARS NEW YORK--(BUSINESS WIRE)--May 21, 2003--Advanced Plant Pharmaceuticals, Inc., (OTCBB:APPI) a company that utilizes whole plants through a proprietary (patent pending) manufacturing process to develop nutraceuticals, has announced the signing of an agreement with Union Bless, Ltd. of Hong Kong. Union Bless, Ltd. has agreed to initiate efficacy trials for ABAVCA and the treatment of SARS virus in SARS patients in Hong Kong, China and the Philippines. ABAVCA, which is patented and manufactured by APPI, is an all-natural immunomodulator that has received an IND (investigational new drug) number from the United States Food and Drug Administration (FDA) and has been approved for Phase I/II clinical studies. In prior clinical studies conducted by APPI, ABAVCA showed promising results in the boosting of the immune system. In case studies of patients using ABAVCA orally, patients experienced the reversal of glandular swelling, restoration of well-being and associated weight gain, improvement in response to skin hypersensitivity tests, increase in blood hemoglobin counts, increase in CD4-counts and improvement in the CD4/CD8 ratio, with many patients returning to a normal ratio. On May 19, 2003, a provisional patent application for ABAVCA and the treatment of SARS was filed with the US Patent and Trademark Office. To date, there have been approximately 7700 cases of persons infected with SARS, with a mortality rate of 8-10%. Patients with a compromised immune system have exhibited a particular vulnerability to SARS.ABAVCA may have the potential to be used as a prophylactic (preventative) and as a treatment for SARS. Although SARS has no geographical boundaries, most of the confirmed cases of SARS have been in China and Hong Kong where Union Bless Ltd. will conduct SARS research. Although APPI makes no claim and has no clinical evidence that ABAVCA is effective on SARS, the clinical trials will be designed to gather the empirical data to prove potential efficacy. For more information on APPI, please visit the Company's Web site at advancedplantpharm.com FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995